🔗 Share this article

The Nobel Prize in medical science was granted for revolutionary discoveries that clarify how the immune system targets dangerous pathogens while sparing the healthy tissues.

A trio of renowned researchers—Japan's Shimon Sakaguchi and US experts Mary Brunkow and Fred Ramsdell—received this honor.

The research identified unique "security guards" within the immune system that eliminate malfunctioning immune cells capable of attacking the body.

These discoveries are now paving the way for innovative treatments for immune disorders and malignancies.

These winners will divide a prize fund valued at 11 million Swedish kronor.

Crucial Discoveries

"The work has been decisive for comprehending how the body's defenses operates and why we do not all suffer from serious self-attack conditions," stated the chair of the Nobel Committee.

The team's research address a core mystery: In what way does the immune system defend us from countless infections while leaving our healthy cells unharmed?

The immune system uses immune cells that scan for indicators of infection, even pathogens and bacteria it has not met before.

Such defenders utilize detectors—known as recognition units—that are produced by chance in a vast number of variations.

This provides the defense network the ability to fight a wide array of invaders, but the unpredictability of the mechanism unavoidably creates white blood cells that can target the body.

Protectors of the Immune System

Researchers earlier knew that a portion of these harmful white blood cells were destroyed in the immune organ—where immune cells develop.

The latest award honors the discovery of regulatory T-cells—described as the body's "peacekeepers"—which patrol the system to disarm other immune cells that assault the healthy cells.

We know that this process malfunctions in self-attack conditions such as type-1 diabetes, MS, and rheumatoid arthritis.

The Nobel panel stated, "The findings have established a new field of investigation and spurred the development of innovative therapies, for example for tumors and autoimmune diseases."

In malignancies, regulatory T-cells block the body from fighting the growth, so studies are focused on reducing their numbers.

For self-attack disorders, trials are testing boosting regulatory T-cells so the organism is not under attack. A similar approach could also be effective in minimizing the chances of organ transplant failure.

Innovative Studies

Professor Sakaguchi, from a Japanese institution, performed experiments on rodents that had their thymus extracted, leading to autoimmune disease.

He demonstrated that introducing immune cells from healthy animals could stop the illness—suggesting there was a mechanism for preventing immune cells from harming the host.

Mary Brunkow, affiliated with the a research center in a US city, and Fred Ramsdell, currently at Sonoma Biotherapeutics in San Francisco, were studying an genetic autoimmune disease in rodents and people that led to the discovery of a genetic factor vital for how T-regs function.

"Their groundbreaking research has revealed how the body's defenses is controlled by T-reg cells, preventing it from accidentally attacking the healthy cells," commented a leading physiology specialist.

"This work is a striking example of how basic biological study can have far-reaching consequences for public health."